Results 171 to 180 of about 38,593 (257)

Mortality Trend in Patients With Heart Failure and Psychoactive Substance Abuse in the United States—Pre‐ and Post‐COVID‐19 Pandemic Perspective (1999−2023)

open access: yesClinical Cardiology, Volume 49, Issue 8, August 2026.
From 1999 to 2023, national HF‐substance abuse‐related mortality rates in adults rose over 10‐fold, disproportionately affecting males, older adults, and NH White and NH Black populations. Geographically, nonmetropolitan areas and the Midwestern/Northwestern regions saw the highest burden, signaling an urgent need for integrated cardiovascular and ...
Emad Uddin Sajid   +9 more
wiley   +1 more source

National Trends & Disparities in Ischemic Heart Disease & Cardiac Arrhythmias Related Mortality in the United States From 1999 to 2024: A CDC Wonder Analysis

open access: yesClinical Cardiology, Volume 49, Issue 8, August 2026.
This graphical abstract summarizes long‐term national trends and demographic disparities in mortality related to co‐occurring ischemic heart disease (IHD) and cardiac arrhythmias in the United States between 1999 and 2024, derived from the Centers for Disease Control and Prevention Wide‐ranging Online Data for Epidemiologic Research (CDC WONDER ...
Muhammad Murtaza   +10 more
wiley   +1 more source

Hypertensive Emergency During Dialysis: A Paradoxical Physiologic Response. [PDF]

open access: yesCureus
Imburgio S   +7 more
europepmc   +1 more source

Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large‐Scale Propensity Score–Matched Real‐World Analysis

open access: yesClinical Cardiology, Volume 49, Issue 8, August 2026.
In this large real‐world propensity‐matched analysis, tirzepatide demonstrated superior reductions in mortality, hospitalizations, and cardiorenal outcomes versus dulaglutide in HFpEF patients, with a favorable safety profile. ABSTRACT Background No direct head‐to‐head trials compare tirzepatide and dulaglutide in heart failure with preserved ejection ...
Ibrahim Khalil   +8 more
wiley   +1 more source

Artificial Intelligence for Hypertension Risk Prediction and Management: A Systematic Review

open access: yesEngineering Reports, Volume 8, Issue 8, August 2026.
AI‐based hypertension systems integrate wearable monitoring, clinical records, explainable prediction, lifestyle guidance, medication follow‐up, and early‐warning alerts to support earlier risk detection and personalized management. This systematic review of 40 studies highlights strong predictive potential while emphasizing the need for real‐world ...
Farzana Khanum Oyshi   +5 more
wiley   +1 more source

A case of hypertensive emergency with alveolar hemorrhage and thrombotic microangiopathy. [PDF]

open access: yesCEN Case Rep
Ubara Y   +14 more
europepmc   +1 more source

Respiratory Viral Burden and Healthcare Utilization Among Pediatric Patients With Acute Respiratory Viral Infections in a Tertiary Care Center

open access: yesHealth Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Respiratory viral infections, particularly Respiratory Syncytial Virus (RSV) and influenza, are major causes of pediatric morbidity, hospitalization, and healthcare strain during winter seasons. This study aims to evaluate the clinical and epidemiological burden of RSV and influenza in pediatric patients and assess associated ...
Shafiqa Alsharif
wiley   +1 more source

Labetalol, Nifedipine, and Methyldopa for the Management of Hypertensive Disorders in Pregnancy in Iran: A Cost‐Effectiveness Analysis

open access: yesHealth Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Hypertensive disorders in pregnancy create major clinical and economic burdens on maternal health services, making evidence on efficient resource allocation and cost‐effectiveness essential for treatment decisions. However, no clear consensus exists on the most cost‐effective antihypertensive therapy in Iran.
Zahra Goudarzi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy